Abstract:OBJECTIVE To evaluate the efficacy of inoculation with pneumococcal polysaccharide vaccine and/or influenza vaccine in protecting against recurrent episodes of acute exacerbations of chronic obstructive pulmonary disease(COPD). METHODS During September 2016 to October 2017, patients in stable COPD were carried out to obtain randomized controlled trials of influenza vaccine group (group A, n=22), pneumococcal polysaccharide vaccine combined with influenza vaccine group (group B, n=17) and control group(group C, n=20). The frequency of acute attack, the rates of hospitalization, the average days of hospitalization, the days of acute attack distance and the rates combined with community-acquired pneumonia(CAP) in a year were compared in three groups. RESULTS Comparing with control group，the frequency of acute attack, the rates of hospitalization and the average days of hospitalization were significantly reduced in group A and group B(P<0.05)．However, there are no significant different between group A and B (P=0.909, 0.625, 0.118, respectively). The incidence of combined with CAP reduced significantly both in group A and group B compared to control group (P<0.05), at the same time, there was significant difference between group A and group B(P=0.013). CONCLUSION The vaccine could effectively prevent the acute exacerbation of COPD, reduce the rates and the average days of hospitalization and reduce risk for CAP.